Lilly Stipple Bio Deal: Why Eli Lilly Is Betting Up to $5.9B on Tumor-Only Targets
Eli Lilly signed a multi-target oncology pact with Stipple Bio worth up to $5.9 billion in milestones. We break down the terms, the Pointillist platform and the ADC market it targets.
